Voyager Therapeutics Announces 2024 Annual Meeting of Stockholders on June 5
Ticker: VYGR · Form: DEF 14A · Filed: Apr 25, 2024 · CIK: 1640266
Sentiment: neutral
Topics: proxy statement, annual meeting, director election, executive compensation, auditor ratification
TL;DR
<b>Voyager Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, to elect directors, approve executive compensation, and ratify auditor appointments.</b>
AI Summary
Voyager Therapeutics, Inc. (VYGR) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Voyager Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 9:00 a.m. ET. The meeting will take place in person at the company's offices located at 75 Hayden Avenue, Lexington, Massachusetts. Key agenda items include the election of three Class III directors: Michael Higgins, Jude Onyia, Ph.D., and Nancy Vitale. Stockholders will also vote on a non-binding advisory basis for the compensation of named executive officers. The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024 will be ratified.
Why It Matters
For investors and stakeholders tracking Voyager Therapeutics, Inc., this filing contains several important signals. The annual meeting is a critical governance event where shareholders directly influence the company's leadership and oversight. Shareholder approval of executive compensation and auditor ratification are standard but important votes that reflect confidence in management and financial reporting.
Risk Assessment
Risk Level: low — Voyager Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational changes indicated.
Analyst Insight
Stockholders should review the director nominees and executive compensation proposals before the June 5th meeting.
Key Numbers
- June 5, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
- 9:00 a.m. ET — Annual Meeting Time (2024 Annual Meeting of Stockholders)
- 3 — Directors to be Elected (Class III directors)
- 2027 — Director Term End (until the 2027 annual meeting of stockholders)
- December 31, 2024 — Fiscal Year End (Independent registered public accounting firm for the fiscal year ending December 31, 2024)
- April 8, 2024 — Record Date (Stockholders of record at the close of business on April 8, 2024)
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Registrant
- June 5, 2024 (date) — Date of Annual Meeting
- Michael Higgins (person) — Director Nominee
- Jude Onyia, Ph. D. (person) — Director Nominee
- Nancy Vitale (person) — Director Nominee
- Ernst & Young LLP (company) — Independent Registered Public Accounting Firm
- April 8, 2024 (date) — Record Date for Voting
FAQ
When did Voyager Therapeutics, Inc. file this DEF 14A?
Voyager Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 25, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Voyager Therapeutics, Inc. (VYGR).
Where can I read the original DEF 14A filing from Voyager Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Voyager Therapeutics, Inc..
What are the key takeaways from Voyager Therapeutics, Inc.'s DEF 14A?
Voyager Therapeutics, Inc. filed this DEF 14A on April 25, 2024. Key takeaways: Voyager Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 9:00 a.m. ET.. The meeting will take place in person at the company's offices located at 75 Hayden Avenue, Lexington, Massachusetts.. Key agenda items include the election of three Class III directors: Michael Higgins, Jude Onyia, Ph.D., and Nancy Vitale..
Is Voyager Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Voyager Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational changes indicated.
What should investors do after reading Voyager Therapeutics, Inc.'s DEF 14A?
Stockholders should review the director nominees and executive compensation proposals before the June 5th meeting. The overall sentiment from this filing is neutral.
How does Voyager Therapeutics, Inc. compare to its industry peers?
Voyager Therapeutics is a biotechnology company focused on developing gene therapies for neurodegenerative diseases.
Are there regulatory concerns for Voyager Therapeutics, Inc.?
The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.
Industry Context
Voyager Therapeutics is a biotechnology company focused on developing gene therapies for neurodegenerative diseases.
Regulatory Implications
The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.
What Investors Should Do
- Review the biographies and qualifications of the director nominees.
- Understand the details of the executive compensation plan being presented for advisory approval.
- Confirm the ratification of Ernst & Young LLP as the independent auditor for FY2024.
Key Dates
- 2024-06-05: 2024 Annual Meeting of Stockholders — Election of directors, advisory vote on executive compensation, and ratification of auditor appointment.
- 2024-04-08: Record Date — Determines which stockholders are entitled to vote at the Annual Meeting.
Year-Over-Year Comparison
This is a DEF 14A filing for the 2024 annual meeting, indicating routine corporate governance procedures.
Filing Stats: 4,847 words · 19 min read · ~16 pages · Grade level 11.5 · Accepted 2024-04-25 17:20:07
Key Financial Figures
- $0.001 — 6 shares of our common stock, par value $0.001 per share, all of which are entitled to
- $15,000 — Solutions, Inc. a fee of approximately $15,000 for their services. Procedure for Subm
Filing Documents
- vygr-20240605xdef14a.htm (DEF 14A) — 1009KB
- vygr-20240605xdef14a_a004.jpg (GRAPHIC) — 47KB
- vygr-20240605xdef14a_a009.jpg (GRAPHIC) — 58KB
- vygr-20240605xdef14a_a010.jpg (GRAPHIC) — 56KB
- vygr-20240605xdef14a_bg001.jpg (GRAPHIC) — 131KB
- vygr-20240605xdef14a_bg002.jpg (GRAPHIC) — 112KB
- 0001558370-24-005793.txt ( ) — 1568KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 11 EXECUTIVE OFFICERS 16 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 17 CORPORATE GOVERNANCE 20
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 31 DIRECTOR COMPENSATION 43 HOUSEHOLDING OF PROXY MATERIALS 45 TRANSACTION OF OTHER BUSINESS 45 Table of Contents VOYAGER THERAPEUTICS, INC. PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS GENERAL INFORMATION Our Board of Directors, or the Board of Directors, has made this proxy statement, or Proxy Statement, and related materials available to you on the Internet, or at your request has delivered printed versions to you by mail, in connection with the Board of Directors' solicitation of proxies for our 2024 Annual Meeting of Stockholders, or the Annual Meeting, and any adjournment or postponement of the Annual Meeting. If you requested printed versions of these materials by mail, they will also include a proxy card for the Annual Meeting. The Annual Meeting is to be held on Wednesday, June 5, 2024, at 9:00 a.m. Eastern Time, at our 3 rd floor offices at 75 Hayden Avenue, Lexington, Massachusetts, 02421. Pursuant to rules adopted by the Securities and Exchange Commission, or the SEC, we are providing access to our proxy materials over the Internet. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials, or the Notice, to our stockholders of record and beneficial owners as of the record date identified below. The mailing of the Notice to our stockholders is scheduled to begin on April 25, 2024. IMPORTANT NOTICE REGARDING THE INTERNET AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 5, 2024: This Proxy Statement, the accompanying proxy card or voting instruction card and our 2023 Annual Report on Form 10-K are available at http://www.proxyvote.com . A copy of our 2023 Annual Report on Form 10-K as filed with the SEC, except for exhibits, will be furnished without charge to any stockholder upon written or oral request to Voyager Therapeutics, Inc., 75 Hayden Avenue, Lexington, MA 02421, Attention: Secretary, Telephone: (857) 259-5340. This P